<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02008565</url>
  </required_header>
  <id_info>
    <org_study_id>PFDN- 18PO1</org_study_id>
    <secondary_id>2U10HD041261</secondary_id>
    <secondary_id>2U10HD054215</secondary_id>
    <secondary_id>2U10HD041267</secondary_id>
    <secondary_id>1U10HD069006</secondary_id>
    <secondary_id>2U10HD054214</secondary_id>
    <secondary_id>1U10HD069013</secondary_id>
    <secondary_id>1U10HD069025</secondary_id>
    <secondary_id>1U10HD069010</secondary_id>
    <secondary_id>1U01HD069031</secondary_id>
    <nct_id>NCT02008565</nct_id>
  </id_info>
  <brief_title>Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)</brief_title>
  <acronym>CAPABLe</acronym>
  <official_title>Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe): a Randomized Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NICHD Pelvic Floor Disorders Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Women and Infants Hospital of Rhode Island</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NICHD Pelvic Floor Disorders Network</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a multi-center, randomized, placebo controlled trial with participants
      randomized into one of four groups:

        1. placebo/usual care (educational pamphlet)

        2. loperamide/usual care (educational pamphlet)

        3. placebo/anal exercises with biofeedback

        4. loperamide/anal exercises with biofeedback

      The primary outcome, change from baseline in St. Marks (Vaizey) Score at 24 weeks, will be
      compared between treatment groups using linear regression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goals of this trial are to compare the use of loperamide to oral placebo and to compare
      the use of anal sphincter exercise training with biofeedback to usual care (educational
      pamphlet) in the treatment of women suffering from fecal incontinence (FI). We will test the
      following null hypotheses:

        1. there is no difference in outcomes between women randomized to loperamide and women
           randomized to oral placebo for treatment of FI;

        2. there is no difference in outcomes between women randomized to anal sphincter exercises
           with biofeedback and women randomized to usual care (educational pamphlet) for FI
           treatment;

        3. there is no difference between women randomized to both treatments together and women
           randomized to either FI treatment alone; and

        4. there is no correlation between anal manometry measurements and digital anal squeeze
           strength or measures of FI severity and bother.

      A supplemental study, Stool Metabolome and Microbiome in Women with Fecal Incontinence in
      CAPABLe, will evaluate the stool metabolome and microbiome in women with fecal incontinence
      and unaffected age matched controls.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline St. Mark's (Vaizey) Score</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>The primary outcome measure for all study arms is the change from baseline in St. Mark's (Vaizey) Score 24 weeks after treatment initiation to compare the marginal outcomes of anal exercise with biofeedback to usual care and loperamide to placebo.
The St. Mark's (Vaizey) score, published in 1999, is commonly used in clinical studies and reports and was based on the Jorge-Wexner score but added two further items for assessment: the use of constipating medication and the presence of fecal urgency. Minimum score is 0 = perfect continence; maximum score is 24 = totally incontinent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life on Colorectal-Anal Distress Inventory (CRADI)</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1) Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2) Colorectal Anal Distress Inventory (range: 0-100), and 3) Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Colorectal-Anal Subscale of the Pelvic Floor Impact Questionnaire Short Form (CRAIQ) Score</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Accident-free Days at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of accident-free days at 12 and 24 weeks and the number of accident-free days at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Pad-change Leaks Per Day at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per day resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Pad-change Leaks Per Week at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per week resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Total Number of Leaks Per Day at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in daily average FI episodes at 12 and 24 weeks and the daily average FI episodes at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Incontinence Severity Index (FISI) Score</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>The Modified Manchester Health Questionnaire (MMHQ) includes the 4-item Fecal Incontinence Severity Index (FISI), which measures the severity of liquid, solid, mucus, or gas incontinence that occurs from &quot;2 or more times per day,&quot; &quot;once per day,&quot; &quot;2 or more times per week,&quot; &quot;once a week,&quot; to &quot;1-3 times per month.&quot; Patient-weighted scores were used to determine severity and scores ranged from 0-61, with higher scores indicating worse fecal incontinence (FI) severity. An FISI score of 0 indicated continence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Improvement in Patient Global Impression of Improvement (PGI-I) Score</measure>
    <time_frame>12 and 24 Weeks</time_frame>
    <description>The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better), or 3 (a little better).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Resting Anal Canal Pressures (mm of Hg) at 2 cm, 1 cm, and 0 cm Insertion at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at 12 and 24 weeks and resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Volume of Air (mL) at First Sensation for Perception of Rectal Distention at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in volume of air (mL) at first sensation for perception of rectal distention at 12 and 24 weeks and volume of air (mL) at first sensation for perception of rectal distention at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Volume of Air (mL) at Urge to Defecate at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in maximum tolerable rectal volume of air (mL) at 12 and 24 weeks and maximum tolerable rectal volume of air (mL) at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline Maximum Anal Pressures During Squeeze With the Catheter at the HPZ at 12 and 24 Weeks</measure>
    <time_frame>12 and 24 weeks</time_frame>
    <description>Based on data collected from the manometry form, the outcome variable will be computed as the difference in maximum anal pressures during squeeze with the catheter at the high pressure zone (HPZ) at 12 and 24 weeks and maximum anal pressures during squeeze with the catheter at the HPZ at baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Placebo - Exercise plus Biofeedback</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and biofeedback intervention. Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loperamide - Exercise plus Biofeedback</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loperamide and biofeedback intervention. Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
Anal exercises with biofeedback intervention is a total of six sessions with trained personnel occurring every 2 weeks over a 12-week period. Sessions are held at the following study visits: baseline, 2, 4, 6, 9, and 12 week visits.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Education Only</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo and education (usual care). Placebo doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
Participants receive education and a NIDDK Bowel Control Educational pamphlet.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Loperamide - Education Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loperamide and education (usual care). Loperamide doses range from 2mg every other day to 8mg per day. Capsules are taken by mouth once a day for 24 weeks.
Participants receive education and a NIDDK Bowel Control Educational pamphlet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loperamide</intervention_name>
    <description>Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.</description>
    <arm_group_label>Loperamide - Education Only</arm_group_label>
    <arm_group_label>Loperamide - Exercise plus Biofeedback</arm_group_label>
    <other_name>Imodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.</description>
    <arm_group_label>Placebo - Education Only</arm_group_label>
    <arm_group_label>Placebo - Exercise plus Biofeedback</arm_group_label>
    <other_name>Inactive Drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Anal exercises with biofeedback</intervention_name>
    <description>Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).</description>
    <arm_group_label>Loperamide - Exercise plus Biofeedback</arm_group_label>
    <arm_group_label>Placebo - Exercise plus Biofeedback</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.</description>
    <arm_group_label>Loperamide - Education Only</arm_group_label>
    <arm_group_label>Placebo - Education Only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Fecal incontinence defined as any uncontrolled loss of liquid or solid fecal material
             that occurs at least monthly over the last 3 months that is bothersome enough to
             desire treatment

        Exclusion Criteria:

          -  Stool consistency over the last 3 months that includes items 1 or 7 based on the
             Bristol Stool form scale

          -  Current or past diagnosis of colorectal or anal malignancy

          -  Diagnosis of inflammatory bowel disease

          -  Current or history of rectovaginal fistula or cloacal defect

          -  Rectal prolapse (mucosal or full thickness)

          -  Prior removal or diversion of any portion of colon or rectum

          -  Prior pelvic floor or abdominal radiation

          -  Refusal or inability to provide written consent

          -  Inability to conduct telephone interviews conducted in English or Spanish

          -  Fecal impaction by exam

          -  Untreated pelvic organ prolapse beyond the hymen; Patients with prolapse beyond the
             hymen who are currently using a pessary are eligible

          -  Incontinence only to flatus

          -  Has taken any loperamide (Imodium®) or diphenoxylate plus atropine (Lomotil®) in the
             last 30 days

          -  Previously received and failed treatment of fecal incontinence using loperamide
             (Imodium®) or diphenoxylate plus atropine (Lomotil®) over the last 3 months

          -  Current supervised anal sphincter exercise/pelvic floor muscle training with
             biofeedback

          -  Previously received and failed treatment of fecal incontinence using supervised anal
             sphincter exercise/pelvic floor muscle training with biofeedback

          -  Previous allergy or intolerance to loperamide

          -  Pregnant, nursing, or planning to become pregnant before the end of the study
             follow-up period.

          -  Childbirth within the last 3 months

          -  Currently taking anti-retroviral drugs

          -  Neurological disorders known to affect continence, including spinal cord injury,
             advanced multiple sclerosis or Parkinson's disease and debilitating stroke

          -  Known diagnosis of hepatic impairment

          -  Chronic abdominal pain in the absence of diarrhea
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J E Jelovsek</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew Barber</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037-0974</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown/Women and Infants Hospital of Rhode Island</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 6, 2013</study_first_submitted>
  <study_first_submitted_qc>December 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <results_first_submitted>February 16, 2018</results_first_submitted>
  <results_first_submitted_qc>October 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2018</results_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fecal incontinence</keyword>
  <keyword>Loperamide</keyword>
  <keyword>anal exercises</keyword>
  <keyword>biofeedback</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loperamide</mesh_term>
    <mesh_term>Antidiarrheals</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Loperamide - Exercise Plus Biofeedback</title>
          <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
        </group>
        <group group_id="P2">
          <title>Placebo - Exercise Plus Biofeedback</title>
          <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
        </group>
        <group group_id="P3">
          <title>Loperamide - Education Only</title>
          <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
        </group>
        <group group_id="P4">
          <title>Placebo - Education Only</title>
          <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="86"/>
                <participants group_id="P4" count="42"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Loperamide - Exercise Plus Biofeedback</title>
          <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
        </group>
        <group group_id="B2">
          <title>Placebo - Exercise Plus Biofeedback</title>
          <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
        </group>
        <group group_id="B3">
          <title>Loperamide - Education Only</title>
          <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
        </group>
        <group group_id="B4">
          <title>Placebo - Education Only</title>
          <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
            <count group_id="B2" value="83"/>
            <count group_id="B3" value="86"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="296"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.2" spread="10.9"/>
                    <measurement group_id="B2" value="63.2" spread="12.2"/>
                    <measurement group_id="B3" value="63.4" spread="10.6"/>
                    <measurement group_id="B4" value="62.6" spread="10.6"/>
                    <measurement group_id="B5" value="63.6" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="86"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="296"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="71"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vaginal deliveries, median [min, max]</title>
          <units>Vaginal deliveries</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="B2" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="B3" value="2.0" lower_limit="0.0" upper_limit="6.0"/>
                    <measurement group_id="B4" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                    <measurement group_id="B5" value="2.0" lower_limit="0.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cesarean deliveries, median [min, max]</title>
          <units>Cesarean deliveries</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.0" lower_limit="0.0" upper_limit="4.0"/>
                    <measurement group_id="B2" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="B3" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="B4" value="0.0" lower_limit="0.0" upper_limit="2.0"/>
                    <measurement group_id="B5" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Menstrual status, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not Sure</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Post-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="74"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="251"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Pre-menopausal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Currently using estrogen therapy, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Oral/Patch</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Vaginal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not currently using estrogen therapy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="57"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current smoker, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not current smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Connective tissue disease, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Connective tissue disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Does not have connective tissue disease</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="83"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior accidental bowel leakage surgery, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior accidental bowel leakage surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior accidental bowel leakage surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="82"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior rectal or anal surgery, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior rectal or anal surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior rectal or anal surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior hysterectomy, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior hysterectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior hysterectomy</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior urinary incontinence surgery, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior urinary incontinence surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior urinary incontinence surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior pelvic organ prolapse surgery, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Prior pelvic organ prolapse surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="70"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No prior pelvic organ prolapse surgery</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="34"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI, mean (SD)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.1" spread="7.4"/>
                    <measurement group_id="B2" value="28.5" spread="6.7"/>
                    <measurement group_id="B3" value="30.9" spread="6.6"/>
                    <measurement group_id="B4" value="30.5" spread="10.4"/>
                    <measurement group_id="B5" value="30.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bristol Stool Index, No. (%)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Type 2 (Sausage shaped but lumpy)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 3 (Like a sausage or snake but with cracks on</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 4 (Like a sausage or snake, smooth and soft)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 5 (Soft blobs with clear cut edges)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Type 6 (Fluffy pieces with ragged edges, a mushy s</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline St. Mark's (Vaizey) Score</title>
        <description>The primary outcome measure for all study arms is the change from baseline in St. Mark's (Vaizey) Score 24 weeks after treatment initiation to compare the marginal outcomes of anal exercise with biofeedback to usual care and loperamide to placebo.
The St. Mark's (Vaizey) score, published in 1999, is commonly used in clinical studies and reports and was based on the Jorge-Wexner score but added two further items for assessment: the use of constipating medication and the presence of fecal urgency. Minimum score is 0 = perfect continence; maximum score is 24 = totally incontinent.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline St. Mark's (Vaizey) Score</title>
          <description>The primary outcome measure for all study arms is the change from baseline in St. Mark's (Vaizey) Score 24 weeks after treatment initiation to compare the marginal outcomes of anal exercise with biofeedback to usual care and loperamide to placebo.
The St. Mark's (Vaizey) score, published in 1999, is commonly used in clinical studies and reports and was based on the Jorge-Wexner score but added two further items for assessment: the use of constipating medication and the presence of fecal urgency. Minimum score is 0 = perfect continence; maximum score is 24 = totally incontinent.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week St. Mark's Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="77"/>
                    <count group_id="O4" value="38"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" lower_limit="-7.2" upper_limit="-3.9"/>
                    <measurement group_id="O2" value="-4.4" lower_limit="-6.0" upper_limit="-2.8"/>
                    <measurement group_id="O3" value="-4.5" lower_limit="-6.1" upper_limit="-2.9"/>
                    <measurement group_id="O4" value="-3.4" lower_limit="-6.0" upper_limit="-0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week St. Mark's Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="75"/>
                    <count group_id="O2" value="74"/>
                    <count group_id="O3" value="80"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.7" lower_limit="-11.9" upper_limit="-7.5"/>
                    <measurement group_id="O2" value="-5.9" lower_limit="-8.1" upper_limit="-3.7"/>
                    <measurement group_id="O3" value="-6.2" lower_limit="-8.1" upper_limit="-4.2"/>
                    <measurement group_id="O4" value="-4.5" lower_limit="-7.1" upper_limit="-1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <p_value_desc>significance assessed at type 1 error alpha=0.05</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The models were adjusted for baseline Irritable Bowel Syndrome (IBS) status and clinical site.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life on Colorectal-Anal Distress Inventory (CRADI)</title>
        <description>The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1) Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2) Colorectal Anal Distress Inventory (range: 0-100), and 3) Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life on Colorectal-Anal Distress Inventory (CRADI)</title>
          <description>The Pelvic Floor Distress Inventory is a 20-question, validated, self-reported instrument used to evaluate pelvic floor symptoms. It consists of an overall scale (range: 0-300) comprised of 3 sub-scales: 1) Pelvic Organ Prolapse Distress Inventory (range: 0-100), 2) Colorectal Anal Distress Inventory (range: 0-100), and 3) Urinary Distress Inventory (range: 0-100). The range of responses on the CRADI is 1-4 with (1) Not at all, (2) Somewhat, (3) Moderately, and (4), Quite a bit. Scores are calculated by multiplying the mean value of all questions answered by 25 for the scale. The range of responses is: 0-100 with 0 (least distress) to 100 (most distress). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week CRADI Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" lower_limit="-22.4" upper_limit="-10.1"/>
                    <measurement group_id="O2" value="-13.1" lower_limit="-19.2" upper_limit="-7.1"/>
                    <measurement group_id="O3" value="-16.9" lower_limit="-22.8" upper_limit="-11.1"/>
                    <measurement group_id="O4" value="-4.6" lower_limit="-14.2" upper_limit="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week CRADI Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.5" lower_limit="-27.6" upper_limit="-15.4"/>
                    <measurement group_id="O2" value="-15.7" lower_limit="-21.7" upper_limit="-9.6"/>
                    <measurement group_id="O3" value="-21.7" lower_limit="-27.6" upper_limit="-15.9"/>
                    <measurement group_id="O4" value="-15.7" lower_limit="-25.4" upper_limit="-5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Colorectal-Anal Subscale of the Pelvic Floor Impact Questionnaire Short Form (CRAIQ) Score</title>
        <description>The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Colorectal-Anal Subscale of the Pelvic Floor Impact Questionnaire Short Form (CRAIQ) Score</title>
          <description>The Pelvic Floor Impact Questionnaire short form (PFIQ-7) measuring the impact of bladder, bowel, and vaginal symptoms on a woman's daily activities, relationships and emotions is composed of 3 scales of 7 questions each: the Urinary Impact Questionnaire (UIQ; range 0-100), the Pelvic Organ Prolapse Impact Questionnaire (POPIQ; range 0-100), and the Colorectal-Anal Impact Questionnaire (CRAIQ; range 0-100). The range of responses on the CRAIQ is 0-3 with (0) Not at all, (1) Somewhat, (2) Moderately, and (3), Quite a bit. Scores are calculated by multiplying the mean value of all answered questions for a scale by 100 divided by 3. The range of responses is: 0-100 with 0 (least negative impact) to 100 (most negative impact). Change = (Week [12, 24] Score - Baseline Score). Lower scores indicate better function / fewer symptoms.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="71"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-18.5" upper_limit="-6.4"/>
                    <measurement group_id="O2" value="-10.8" lower_limit="-16.8" upper_limit="-4.9"/>
                    <measurement group_id="O3" value="-15.8" lower_limit="-21.6" upper_limit="-9.9"/>
                    <measurement group_id="O4" value="-12.3" lower_limit="-21.9" upper_limit="-2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.3" lower_limit="-57.9" upper_limit="-24.6"/>
                    <measurement group_id="O2" value="-32.4" lower_limit="-48.8" upper_limit="-15.9"/>
                    <measurement group_id="O3" value="-41.6" lower_limit="-57.8" upper_limit="-25.4"/>
                    <measurement group_id="O4" value="-17.3" lower_limit="-26.9" upper_limit="-7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Accident-free Days at 12 and 24 Weeks</title>
        <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of accident-free days at 12 and 24 weeks and the number of accident-free days at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Accident-free Days at 12 and 24 Weeks</title>
          <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of accident-free days at 12 and 24 weeks and the number of accident-free days at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>accident-free days</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.1" upper_limit="2.5"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.2" upper_limit="2.6"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="1.4" lower_limit="0.2" upper_limit="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" lower_limit="1.8" upper_limit="3.2"/>
                    <measurement group_id="O2" value="1.9" lower_limit="1.2" upper_limit="2.5"/>
                    <measurement group_id="O3" value="1.7" lower_limit="1.0" upper_limit="2.4"/>
                    <measurement group_id="O4" value="2.1" lower_limit="0.9" upper_limit="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Pad-change Leaks Per Day at 12 and 24 Weeks</title>
        <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per day resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Pad-change Leaks Per Day at 12 and 24 Weeks</title>
          <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per day resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>pad-change leaks per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" lower_limit="-0.7" upper_limit="-0.1"/>
                    <measurement group_id="O2" value="-0.2" lower_limit="-0.4" upper_limit="0.1"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.5" upper_limit="0.0"/>
                    <measurement group_id="O4" value="-0.2" lower_limit="-0.7" upper_limit="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-0.8" upper_limit="-0.2"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-0.4" upper_limit="0.2"/>
                    <measurement group_id="O3" value="-0.4" lower_limit="-0.7" upper_limit="-0.1"/>
                    <measurement group_id="O4" value="-0.4" lower_limit="-0.8" upper_limit="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Pad-change Leaks Per Week at 12 and 24 Weeks</title>
        <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per week resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Pad-change Leaks Per Week at 12 and 24 Weeks</title>
          <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in number of fecal incontinence episodes per week resulting in a change in pad, clothes or underwear at 12 and 24 weeks and the number of fecal incontinence episodes resulting in a change in pad, clothes or underwear at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at least 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>pad-change leaks per week</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" lower_limit="-4.5" upper_limit="-0.9"/>
                    <measurement group_id="O2" value="-1.1" lower_limit="-2.9" upper_limit="0.6"/>
                    <measurement group_id="O3" value="-1.3" lower_limit="-3.1" upper_limit="0.4"/>
                    <measurement group_id="O4" value="-1.7" lower_limit="-4.8" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" lower_limit="-5.2" upper_limit="-1.5"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-2.5" upper_limit="1.0"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-3.9" upper_limit="-0.4"/>
                    <measurement group_id="O4" value="-2.5" lower_limit="-5.6" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Total Number of Leaks Per Day at 12 and 24 Weeks</title>
        <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in daily average FI episodes at 12 and 24 weeks and the daily average FI episodes at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Total Number of Leaks Per Day at 12 and 24 Weeks</title>
          <description>Based on data collected from participant-completed diaries at baseline and 12 and 24 weeks, the outcome variable is computed as the difference in daily average FI episodes at 12 and 24 weeks and the daily average FI episodes at baseline. Only valid diaries were included in the analyses (e.g. completion of all 7 days for baseline and at 3 complete days, not necessarily consecutive, for follow-up diaries).</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>leaks per day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
                <count group_id="O2" value="82"/>
                <count group_id="O3" value="85"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="73"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="71"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" lower_limit="-1.6" upper_limit="-0.6"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.2" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.9" lower_limit="-1.4" upper_limit="-0.4"/>
                    <measurement group_id="O4" value="-1.0" lower_limit="-1.8" upper_limit="-0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="78"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.8" upper_limit="-0.8"/>
                    <measurement group_id="O2" value="-0.7" lower_limit="-1.1" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-1.0" lower_limit="-1.5" upper_limit="-0.6"/>
                    <measurement group_id="O4" value="-1.3" lower_limit="-2.2" upper_limit="-0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Fecal Incontinence Severity Index (FISI) Score</title>
        <description>The Modified Manchester Health Questionnaire (MMHQ) includes the 4-item Fecal Incontinence Severity Index (FISI), which measures the severity of liquid, solid, mucus, or gas incontinence that occurs from &quot;2 or more times per day,&quot; &quot;once per day,&quot; &quot;2 or more times per week,&quot; &quot;once a week,&quot; to &quot;1-3 times per month.&quot; Patient-weighted scores were used to determine severity and scores ranged from 0-61, with higher scores indicating worse fecal incontinence (FI) severity. An FISI score of 0 indicated continence.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercises with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Fecal Incontinence Severity Index (FISI) Score</title>
          <description>The Modified Manchester Health Questionnaire (MMHQ) includes the 4-item Fecal Incontinence Severity Index (FISI), which measures the severity of liquid, solid, mucus, or gas incontinence that occurs from &quot;2 or more times per day,&quot; &quot;once per day,&quot; &quot;2 or more times per week,&quot; &quot;once a week,&quot; to &quot;1-3 times per month.&quot; Patient-weighted scores were used to determine severity and scores ranged from 0-61, with higher scores indicating worse fecal incontinence (FI) severity. An FISI score of 0 indicated continence.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="86"/>
                <count group_id="O4" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week MMHQ Severity Measures Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.4" lower_limit="-19.0" upper_limit="-5.8"/>
                    <measurement group_id="O2" value="-10.6" lower_limit="-17.1" upper_limit="-4.0"/>
                    <measurement group_id="O3" value="-14.4" lower_limit="-20.8" upper_limit="-7.9"/>
                    <measurement group_id="O4" value="-7.8" lower_limit="-18.5" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week MMHQ Severity Measures Score</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.1" lower_limit="-25.7" upper_limit="-12.5"/>
                    <measurement group_id="O2" value="-15.0" lower_limit="-21.6" upper_limit="-8.4"/>
                    <measurement group_id="O3" value="-19.2" lower_limit="-25.7" upper_limit="-12.7"/>
                    <measurement group_id="O4" value="-20.0" lower_limit="-30.5" upper_limit="-9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Improvement in Patient Global Impression of Improvement (PGI-I) Score</title>
        <description>The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better), or 3 (a little better).</description>
        <time_frame>12 and 24 Weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Improvement in Patient Global Impression of Improvement (PGI-I) Score</title>
          <description>The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better), or 3 (a little better).</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="72"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Weeks</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="70"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="59"/>
                    <measurement group_id="O3" value="60"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Resting Anal Canal Pressures (mm of Hg) at 2 cm, 1 cm, and 0 cm Insertion at 12 and 24 Weeks</title>
        <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at 12 and 24 weeks and resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at baseline</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Resting Anal Canal Pressures (mm of Hg) at 2 cm, 1 cm, and 0 cm Insertion at 12 and 24 Weeks</title>
          <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at 12 and 24 weeks and resting anal canal pressures (mm Hg) at 2 cm, 1 cm, and 0 cm insertion at baseline</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>resting anal canal pressure (mm Hg)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week Maximum Anal Canal Pressure (Rest)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.6" lower_limit="47.6" upper_limit="57.7"/>
                    <measurement group_id="O2" value="49.4" lower_limit="44.4" upper_limit="54.4"/>
                    <measurement group_id="O3" value="51.1" lower_limit="46.4" upper_limit="55.9"/>
                    <measurement group_id="O4" value="46.3" lower_limit="38.5" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Maximum Anal Canal Pressure (Rest)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.7" lower_limit="42.7" upper_limit="52.7"/>
                    <measurement group_id="O2" value="47.8" lower_limit="42.7" upper_limit="52.9"/>
                    <measurement group_id="O3" value="45.7" lower_limit="40.8" upper_limit="50.5"/>
                    <measurement group_id="O4" value="46.5" lower_limit="38.8" upper_limit="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Week Maximum Anal Canal Pressure (Squeeze)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="74.4" upper_limit="91.6"/>
                    <measurement group_id="O2" value="76.3" lower_limit="67.7" upper_limit="84.9"/>
                    <measurement group_id="O3" value="73.6" lower_limit="65.4" upper_limit="81.8"/>
                    <measurement group_id="O4" value="73.1" lower_limit="59.5" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Maximum Anal Canal Pressure (Squeeze)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="74.4" upper_limit="91.7"/>
                    <measurement group_id="O2" value="74.6" lower_limit="65.9" upper_limit="83.4"/>
                    <measurement group_id="O3" value="67.1" lower_limit="58.8" upper_limit="75.4"/>
                    <measurement group_id="O4" value="72.7" lower_limit="59.3" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Volume of Air (mL) at First Sensation for Perception of Rectal Distention at 12 and 24 Weeks</title>
        <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in volume of air (mL) at first sensation for perception of rectal distention at 12 and 24 weeks and volume of air (mL) at first sensation for perception of rectal distention at baseline.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Volume of Air (mL) at First Sensation for Perception of Rectal Distention at 12 and 24 Weeks</title>
          <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in volume of air (mL) at first sensation for perception of rectal distention at 12 and 24 weeks and volume of air (mL) at first sensation for perception of rectal distention at baseline.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>volume of air (mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week Volume of Air at First Sensation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="76"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" lower_limit="14.8" upper_limit="23.1"/>
                    <measurement group_id="O2" value="22.7" lower_limit="18.5" upper_limit="26.9"/>
                    <measurement group_id="O3" value="21.6" lower_limit="17.6" upper_limit="25.5"/>
                    <measurement group_id="O4" value="25.1" lower_limit="18.6" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Volume of Air at First Sensation</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" lower_limit="15.9" upper_limit="24.3"/>
                    <measurement group_id="O2" value="24.5" lower_limit="20.3" upper_limit="28.7"/>
                    <measurement group_id="O3" value="21.6" lower_limit="17.6" upper_limit="25.6"/>
                    <measurement group_id="O4" value="23.5" lower_limit="17.1" upper_limit="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Volume of Air (mL) at Urge to Defecate at 12 and 24 Weeks</title>
        <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in maximum tolerable rectal volume of air (mL) at 12 and 24 weeks and maximum tolerable rectal volume of air (mL) at baseline.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Volume of Air (mL) at Urge to Defecate at 12 and 24 Weeks</title>
          <description>Based on data collected from the manometry form, the outcome variable is computed as the difference in maximum tolerable rectal volume of air (mL) at 12 and 24 weeks and maximum tolerable rectal volume of air (mL) at baseline.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>volume of air (mL)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="81"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week Volume of Air at Strong Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="67"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="74"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="61.1" upper_limit="77.5"/>
                    <measurement group_id="O2" value="66.9" lower_limit="58.7" upper_limit="75.2"/>
                    <measurement group_id="O3" value="73.0" lower_limit="65.1" upper_limit="80.8"/>
                    <measurement group_id="O4" value="71.8" lower_limit="58.9" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Volume of Air at Strong Urge</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="68"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" lower_limit="67.8" upper_limit="84.2"/>
                    <measurement group_id="O2" value="78.4" lower_limit="70.0" upper_limit="86.7"/>
                    <measurement group_id="O3" value="77.3" lower_limit="69.3" upper_limit="85.3"/>
                    <measurement group_id="O4" value="73.1" lower_limit="60.4" upper_limit="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline Maximum Anal Pressures During Squeeze With the Catheter at the HPZ at 12 and 24 Weeks</title>
        <description>Based on data collected from the manometry form, the outcome variable will be computed as the difference in maximum anal pressures during squeeze with the catheter at the high pressure zone (HPZ) at 12 and 24 weeks and maximum anal pressures during squeeze with the catheter at the HPZ at baseline.</description>
        <time_frame>12 and 24 weeks</time_frame>
        <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Loperamide - Exercise Plus Biofeedback</title>
            <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - Exercise Plus Biofeedback</title>
            <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
          </group>
          <group group_id="O3">
            <title>Loperamide - Education Only</title>
            <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Education Only</title>
            <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline Maximum Anal Pressures During Squeeze With the Catheter at the HPZ at 12 and 24 Weeks</title>
          <description>Based on data collected from the manometry form, the outcome variable will be computed as the difference in maximum anal pressures during squeeze with the catheter at the high pressure zone (HPZ) at 12 and 24 weeks and maximum anal pressures during squeeze with the catheter at the HPZ at baseline.</description>
          <population>An intent-to-treat (ITT) analysis was performed for primary analyses. ITT analysis included all eligible participants who were randomized. The primary analyses included randomized patients who provided outcome data at 12 or 24 weeks.</population>
          <units>max. anal canal pressure squeeze (mmHg)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="83"/>
                <count group_id="O3" value="84"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 Week Maximum Anal Canal Pressure (Squeeze)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="75"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="74.4" upper_limit="91.6"/>
                    <measurement group_id="O2" value="76.3" lower_limit="67.7" upper_limit="84.9"/>
                    <measurement group_id="O3" value="73.6" lower_limit="65.4" upper_limit="81.8"/>
                    <measurement group_id="O4" value="73.1" lower_limit="59.5" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Week Maximum Anal Canal Pressure (Squeeze)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="73"/>
                    <count group_id="O4" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.0" lower_limit="74.4" upper_limit="91.7"/>
                    <measurement group_id="O2" value="74.6" lower_limit="65.9" upper_limit="83.4"/>
                    <measurement group_id="O3" value="67.1" lower_limit="58.8" upper_limit="75.4"/>
                    <measurement group_id="O4" value="72.7" lower_limit="59.3" upper_limit="86.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <desc>All events reported by the participants at study visits and EMR review from randomization until 24 weeks</desc>
      <group_list>
        <group group_id="E1">
          <title>Loperamide - Exercise Plus Biofeedback</title>
          <description>Participants receive loperamide drug and anal exercise with biofeedback intervention.</description>
        </group>
        <group group_id="E2">
          <title>Placebo - Exercise Plus Biofeedback</title>
          <description>Participants receive placebo drug and anal exercise with biofeedback intervention.</description>
        </group>
        <group group_id="E3">
          <title>Loperamide - Education Only</title>
          <description>Participants receive loperamide drug and educational pamphlet (usual care).</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Education Only</title>
          <description>Participants receive placebo drug and educational pamphlet (usual care).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="84"/>
                <counts group_id="E3" subjects_affected="60" subjects_at_risk="88"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="84"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="61" subjects_affected="44" subjects_at_risk="86"/>
                <counts group_id="E2" events="22" subjects_affected="19" subjects_at_risk="84"/>
                <counts group_id="E3" events="42" subjects_affected="33" subjects_at_risk="88"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E4" events="8" subjects_affected="7" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="86"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="84"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="86"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="84"/>
                <counts group_id="E3" events="14" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="84"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marie Gantz</name_or_title>
      <organization>RTI International</organization>
      <phone>919-597-5110</phone>
      <email>mgantz@rti.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

